Ambiguity in the scope of the GMO definition in current legislation: does it also cover organisms that are not “altered” but created, for example using AI?
14-05-2025
Joint open letter COGEM and ZKBS on the ERA of new vaccine developments based on samRNAs and VRPs
In this Joint open letter to the European Commission, the Netherlands Commission on G...
18-10-2024
The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products
In this policy report COGEM explores how many gene therapies are in the development p...
10-10-2019
No rose without thorns
The current legislation on genetically modified (GM) crops in the European Union (EU)...
21-09-2017
Editing Human DNA. Moral and social implications of germline genetic modification
This report is about germline genetic modification (also called germline modification...
15-03-2010
General Surveillance
In Europe, authorisation holders for GM crops are required to monitor for the occurre...
09-07-2010
The status of oligonucleotides within the context of site-directed mutagenesis
COGEM has been requested by VROM to advise on the question whether an oligonucleotide...
07-10-2009
Socio-economic aspects of GMO’s
The minister of Housing, Spatial Planning and the Environment (VROM), Jacqueline Cram...
16-06-2009
Zinc finger on the pulse: Developments and implications of zinc finger technology
COGEM continually monitors new techniques that blur the distinction between genetic m...
26-06-2009
Should EU legislation be updated? Scientific developments throw new light on the process and product approaches
The EU legislation on genetically modified organisms (GMOs) is no longer in step with...